Yourgene Health welcomes Jonathan Seaton to its Board as Non-Executive Director

– UK, Manchester –  Yourgene Health PLC (LON: YGEN), a leading international molecular diagnostics group, today announced the appointment of Jonathan Seaton to the Board of Directors as a Non-Executive Director, with immediate effect.

Adam Reynolds, Chairman of Yourgene, commented: “We’re delighted to welcome Jonathan as a further strengthening of the Board. Jonathan brings over 20 years’ experience working in highly relevant market segments at a time when the Group is very much focused on growth. His experience in commercialisation strategy, M&A and business development within the industry majors, as well as his extensive US contact base, will be invaluable for the Company as we concentrate on delivering our investment plan to drive material increases in shareholder value in the next 3-5 years.”

About Jonathan Seaton

Jonathan has extensive experience working for leading global life sciences and diagnostics companies having worked on more than 40 M&A transactions as well as strategic and commercial development activities. This includes seven years at Roche Diagnostics in Switzerland, where he held the position of Vice Director, Global Business Development, leading M&A activity and strategic partnerships. He then moved to the US to work for Becton, Dickinson and Company in 2015 where he focused on key strategic programmes and Illumina in 2017 where he was Head of Corporate and Business Development and Government Affairs. Jonathan is currently based in the US and is a Director at GenomOncology a privately-held real-time clinical decision-making oncology informatics company. Prior to Roche Diagnostics, he worked as a life sciences investment banker for Deutsche Bank Securities.

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. A careful analysis of the pharmacological effects and clinical effects of many popular sleeping pills reveals that most of them cannot be considered as the best solution to correcting the manifestations of situational insomnia. Reception of Ambien at the in some cases is associated with negative subjective feelings including weakness, depressed mood, metallic or bitter taste in the mouth, and sometimes nausea and vomiting. The Group’s products include non-invasive prenatal tests for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, the UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.